pirenzepine has been researched along with Diabetes Mellitus, Type 2 in 20 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
Excerpt | Relevance | Reference |
---|---|---|
"The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 7.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
"The increasing use of olanzapine for treating adolescent patients has brought with it greater awareness of the recognized side effects of this medication, especially weight gain." | 3.72 | Hyperglycemia from olanzapine treatment in adolescents. ( Bloch, Y; Gothelf, D; Levkovitz, Y; Mendlovic, S; Ratzoni, G; Vardi, O, 2003) |
" However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
"Peak plasma glucose in NIDDMs was reduced following pirenzepine (12." | 2.67 | Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics. ( Ara, J; Bevan, JS; Page, MD; Peters, JR; Scanlon, MF, 1991) |
"The odds of newly reported type 2 diabetes in patients who received risperidone were not significantly different from those in untreated patients (12-month odds ratio [OR] = 1." | 1.32 | Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders. ( Gianfrancesco, F; Grogg, A; Mahmoud, R; Meletiche, D; Wang, RH, 2003) |
"Patients reporting preexisting type 2 diabetes up to 8 months prior to observation were excluded." | 1.31 | Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database. ( Gianfrancesco, FD; Grogg, AL; Mahmoud, RA; Nasrallah, HA; Wang, RH, 2002) |
"A 45-year-old man with well-controlled type 2 diabetes mellitus experienced an abrupt worsening of his diabetes after 3 years of olanzapine therapy His hemoglobin A1c (HbA1c) level rose from a baseline of 5." | 1.31 | Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. ( Bechara, CI; Goldman-Levine, JD, 2001) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 5 (25.00) | 18.2507 |
2000's | 15 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Spivak, B | 1 |
Alamy, SS | 1 |
Jarskog, LF | 1 |
Sheitman, BB | 1 |
Lieberman, JA | 1 |
Wirshing, DA | 2 |
Boyd, JA | 1 |
Meng, LR | 1 |
Ballon, JS | 1 |
Marder, SR | 2 |
Wirshing, WC | 2 |
Gianfrancesco, FD | 1 |
Grogg, AL | 1 |
Mahmoud, RA | 1 |
Wang, RH | 2 |
Nasrallah, HA | 1 |
Issa, BG | 1 |
Davies, N | 1 |
Hood, K | 1 |
Premawardhana, LD | 1 |
Peters, JR | 2 |
Scanlon, MF | 2 |
Bloch, Y | 1 |
Vardi, O | 1 |
Mendlovic, S | 1 |
Levkovitz, Y | 1 |
Gothelf, D | 1 |
Ratzoni, G | 1 |
Gianfrancesco, F | 1 |
Grogg, A | 1 |
Mahmoud, R | 1 |
Meletiche, D | 1 |
Béliard, S | 1 |
Valero, R | 1 |
Vialettes, B | 1 |
Wetterling, T | 1 |
Martina, V | 1 |
Pontiroli, AE | 1 |
Tagliabue, M | 1 |
Calderara, A | 1 |
Maccario, M | 1 |
Pacchioni, M | 1 |
Bertaina, S | 1 |
Bruno, G | 1 |
Pozza, G | 1 |
Camanni, F | 1 |
Spellberg, BJ | 1 |
Erhart, SM | 1 |
Ter Braak, GI | 1 |
Fertig, MK | 1 |
Brooks, VG | 1 |
Shelton, PS | 1 |
English, CW | 1 |
Mir, S | 1 |
Taylor, D | 1 |
Dervaux, A | 1 |
Mascarenhas, N | 1 |
Lambolez, T | 1 |
Ananth, J | 1 |
Gunatilake, S | 1 |
Aquino, S | 1 |
Bach, V | 1 |
Costa, J | 1 |
Littrell, KH | 1 |
Petty, RG | 1 |
Peabody, CD | 1 |
Hilligoss, NM | 1 |
Johnson, CG | 1 |
Bechara, CI | 1 |
Goldman-Levine, JD | 1 |
Sernyak, MJ | 1 |
Leslie, DL | 1 |
Alarcon, RD | 1 |
Losonczy, MF | 1 |
Rosenheck, R | 1 |
Opp, D | 1 |
Hildebrandt, C | 1 |
Bevan, JS | 1 |
Ara, J | 1 |
Page, MD | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
An Open Label Trial of Ziprasidone as an Adjuvant for Clozapine- or Olanzapine-Associated Diabetes Mellitus or Impaired Fasting Glucose in Chronic Schizophrenia[NCT00351000] | Phase 4 | 24 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
A Double-Blind, Placebo-Controlled Trial of Rosiglitazone for Clozapine Induced Glucose Metabolism Impairment: Bergman's Minimal Model Analysis[NCT00337350] | Phase 4 | 20 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting glucose levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
Intervention | mg/dL (Mean) |
---|---|
Clozapine Treatment With Adjunctive Ziprasidone | 5 |
Olanzapine Treatment With Adjunctive Ziprasidone | -4.5 |
Subjects on clozapine with adjunctive ziprasidone were compared to subjects on olanzapine with adjunctive ziprasidone on change in fasting insulin levels from baseline to study endpoint (week 6 - baseline) (NCT00351000)
Timeframe: baseline, week 6
Intervention | microIU/L (Mean) |
---|---|
Clozapine Treatment With Adjunctive Ziprasidone | 1 |
Olanzapine Treatment With Adjunctive Ziprasidone | -0.9 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
Intervention | participants (Number) |
---|---|
Active | 2 |
Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
Intervention | participants (Number) |
---|---|
Active | 1 |
Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
Intervention | µV (Mean) |
---|---|
Active | 56.5 |
Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
Intervention | µV (Mean) |
---|---|
Active | 56 |
Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
Intervention | units on a scale (Mean) |
---|---|
Active | 29.5 |
Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
Intervention | kg/m^2 (Mean) |
---|---|
Aripiprazole | -0.52 |
Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
Intervention | min^-1 (Mean) |
---|---|
Aripiprazole | 0.003 |
Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
Intervention | HOMA score (Mean) |
---|---|
Aripiprazole | 0.6 |
Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
Intervention | mg/dL (Mean) |
---|---|
Aripiprazole | -15.3 |
Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
Intervention | mg/dL (Mean) |
---|---|
Aripiprazole | -5.9 |
Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
Intervention | kg (Mean) |
---|---|
Aripiprazole | -1.5 |
Placebo | 0.3 |
Acute insulin response to glucose (AIRG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. AIRG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. AIRG measures the acute(0-10 min) beta cell response to a glucose load calculated by the areas under the curve higher than basal insulin values. The AIRG was assessed as the incremental area under the curve (calculated by the trapezoid rule) from 0 to 10 min of the FSIVGTT. (NCT00337350)
Timeframe: baseline, week 8
Intervention | Units/mL per 10 minutes (Mean) |
---|---|
Rosiglitazone | -151 |
Placebo | 19 |
Insulin Sensitivity (IS) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in IS between Baseline and week 8. SI was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SI represents the increase in net fractional glucose clearance rate per unit change in serum insulin concentration after the intravenous glucose load (microUnits/mL). (NCT00337350)
Timeframe: baseline, week 8
Intervention | microUnits/mL (Mean) |
---|---|
Rosiglitazone | 3.2 |
Placebo | 0.4 |
Glucose utilization (SG) was assessed using a Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT), performed at Baseline and at week 8 (study endpoint). Subjects in the Rosiglitazone treatment arm were compared to subjects in the placebo treatment arm on their change in SG between Baseline and week 8. SG was calculated from plasma glucose and serum insulin values using the MINMOD Millennium computer program. SG represents the net fractional glucose clearance rate because of the increase in glucose independent of any increase in circulating insulin concentrations above baseline. (NCT00337350)
Timeframe: baseline, week 8
Intervention | min^-1 (Mean) |
---|---|
Rosiglitazone | .002 |
Placebo | -0.01 |
2 reviews available for pirenzepine and Diabetes Mellitus, Type 2
Article | Year |
---|---|
[Type 2 diabetes and dyslipidemia. Side effects of "Atypical" neuroleptics?].
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Diabetes Mellitus, Type 2; Humans; Hy | 2003 |
Atypical antipsychotics and hyperglycaemia.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dia | 2001 |
3 trials available for pirenzepine and Diabetes Mellitus, Type 2
Article | Year |
---|---|
Effect of 2-week treatment with pirenzepine on fasting and postprandial glucose concentrations in individuals with type 2 diabetes.
Topics: Blood Glucose; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Humans; | 2003 |
Pirenzepine decreases basal and stimulated GH secretion in patients with type 2 (non-insulin-dependent) diabetes mellitus.
Topics: Adult; Arginine; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Double-Blind Method; Fe | 1994 |
Cholinergic blockade with pirenzepine induces dose-related reduction in glucose and insulin responses to a mixed meal in normal subjects and non-insulin dependent diabetics.
Topics: Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Dose-Respo | 1991 |
15 other studies available for pirenzepine and Diabetes Mellitus, Type 2
Article | Year |
---|---|
Ziprasidone alternative for olanzapine-induced hyperglycemia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Humans; Hyperglycemia; Male | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Comorbidity; Confidence Inte | 2002 |
Hyperglycemia from olanzapine treatment in adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; | 2003 |
Differential effects of antipsychotic agents on the risk of development of type 2 diabetes mellitus in patients with mood disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Data Collection; Diabetes Mellitus, Type 2; Female; Hu | 2003 |
Atypical neuroleptics and diabetes.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Disease Pro | 2003 |
Novel antipsychotics and new onset diabetes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Humans; Male; Mi | 1998 |
[The hyperglycemic dehydration syndrome].
Topics: Adult; Antidepressive Agents; Benzodiazepines; Clomipramine; Dehydration; Depressive Disorder; Diabe | 1998 |
Hyperglycemia associated with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 1998 |
[Importance of blood glucose level when starting antipsychotic treatment].
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Female; Humans; Mid | 2001 |
Are African American patients at a higher risk for olanzapine-induced glucose intolerance?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Black People; Blood Glucose; Diabetes Mellitus, Type 2 | 2001 |
Treatment of preexisting diabetes with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Drug Administrat | 2001 |
Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy.
Topics: Benzodiazepines; Blood Glucose; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hyperglycemi | 2001 |
Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Antipsychotic Agents; Benzodiazepines; Clozapi | 2002 |
Olanzapine-associated type 2 diabetes mellitus.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body Weight; Diabetes Mellitus, Type | 2002 |